Plain-English translation of NCT07102368 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting real-world information about how guselkumab works for people with Crohn's disease or ulcerative colitis in Germany. Researchers want to see how effective this medication is at reducing symptoms and improving quality of life for different groups of patients. The study will gather information from your regular doctor visits and ask you about your experience with the treatment.
While medications like this one have been tested in controlled research settings, doctors want to understand how well this treatment actually works for patients in everyday medical practice. This study will also help researchers learn about important aspects of life with IBD that matter most to patients—like fatigue, work productivity, and overall well-being.
You likely qualify if…
You likely don't qualify if…
You would continue taking guselkumab as prescribed by your doctor, with no special study visits required. Researchers will collect information from your routine doctor appointments at weeks 0, 4, 8, 12, 24, 48, 72, and 96 (about two years total). You will also be asked to complete short surveys about how you're feeling—including questions about tiredness, quality of life, work productivity, and satisfaction with your treatment.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Germany
Sponsor
Janssen-Cilag G.m.b.H
Enrollment target
~500 participants
Started
August 2025
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen-Cilag G.m.b.H
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.